Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors
Phase 2
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Applied Biosciences
- Target Recruit Count
- 30
- Registration Number
- NCT00007449
- Locations
- 🇺🇸
Bach and Godofsky, Bradenton, Florida, United States
🇺🇸Orange Coast Med Group, Newport Beach, California, United States
🇺🇸Saint Josephs Comprehensive Research Institute, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath